![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif)
PD0325901 An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif) | MEK inhibitor PD0325901 | | ![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081025061338im_/http://www.cancer.gov/images/spacer.gif) |